Cadila Healthcare

Cadila Healthcare share price surges 7% as DCGI approves ZyCoV-D vaccine

ZyCoV-D is the world’s first Plasmid DNA Vaccine for COVID-19 and the sixth vaccine to get approval from India.

Zydus Cadila’s ZyCoV-D vaccine to launch in September; Price to be disclosed in 1-2 weeks

ZyCoV-D, is a needle-free vaccine practised by PharmaJet. It consists of a needle-free applicator, which ascertains painless intradermal vaccine delivery to the user. This is a remarkable achievement by the Plasmid DNA platform, for developing a technologically advanced vaccine suitable for human use.

India records 2.59 lakh fresh COVID-19 cases, 1761 deaths in last 24 hours

Liberalised and accelerated Phase-3 strategy of COVID-19 vaccination from May 1 will let everyone above the age of 18 years to get vaccine.

Cadila Healthcare Q3 results: Profit increased by 41%

Q4 results: Cadila Healthcare posted a net loss of Rs. 392 crore; Bajaj Electricals revenue slips by 27%